Brief: Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
07/04/2026 12:30
April 7 (Reuters) - Pulse Biosciences Inc PLSE.O: PULSE BIOSCIENCES ENROLLS FIRST PATIENTS IN NANOPULSE-AF IDE PIVOTAL CLINICAL STUDY EVALUATING NPULSE™ CARDIAC CATHETER SYSTEM FOR ATRIAL FIBRILLATION Source text: ID:nBw3KqMPma Further company coverage: PLSE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulse Biosciences
See all newsBrief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants
Chairmen Total Approximately $13.3 Million
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Brief: Pulse Biosciences Q1 Net Income USD -18.581 Million
Brief: Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System